Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPITAL OPTI-CROSS
NCT02054663Phase 4
Key facts
- Status
- Completed
- Start
- Dec 2013
- Primary completion
- Feb 2015
- Countries
- 1
- Sponsor
- University of Ottawa Heart Institute
- Modality
- Small Molecules
- Drugs
- clopidogrel
- Conditions
- acute coronary syndrome (ACS)
01
Overview
Phase 4, randomised, open-label trial of clopidogrel in acute coronary syndrome (ACS) (2 arms), sponsored by University of Ottawa Heart Institute. Primary endpoint: Platelet inhibition (P2Y12 reaction Unit) at 72 hours. Started Dec 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Bolus
600mg Clopidogrel bolus then 75mg daily
No Bolus
75mg Clopidogrel daily
03
Who it enrols
Adult patients admitted for ACS on ticagrelor being transitioned to clopidogrel, without bleeding/intolerance to clopidogrel or thrombocytopenia.
04
Endpoints
Primary
Platelet inhibition (P2Y12 reaction Unit)
Secondary
Platelet inhibition (P2Y12 reaction Unit)
Beyond the preview
Go deeper on NCT02054663.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054663.